CSV October 31, 2022 through October 31, 2024 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MILRINONE	ASSAY/	*USP42–NF37*	2922	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Buffer*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Procedure							Change 72.44 g of sodium tetraborate to: 72.44 g of sodium tetraborate, anhydrous
TILETAMINE HYDROCHLORIDE	*Identification/B. Ultraviolet Absorption <197U>*	*USP42–NF37*	4347	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Solution*: Change 0.3 mg per mL. to: 0.03 mg per mL.
REAGENTS AND REFERENCE TABLES	SOLUTIONS/*0.01 M Edetate Disodium VS*	*USP42–NF37*	6179	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Standardization*: Change previously dried at 100° to: previously dried at 110°
CEFTIOFUR HYDROCHLORIDE	IMPURITIES/*High Molecular Weight Impurities*	*USP42–NF37*	857	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Analysis*: Change r_C = peak response of ceftiofur from the *Sample solution* (mg/mL)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								r_A = sum of the responses of all peaks that elute after ceftiofur from the *Sample solution* (mg/mL) to: r_C = peak response of ceftiofur from the *Sample solution* r_A = sum of the responses of all peaks that elute after ceftiofur from the *Sample solution*
PHENYLBUTAZONE INJECTION	*Assay*	*USP42–NF37*	3487	31-May-2019	1-Jun-2019	*NA*	*NA*	Change $350(C/V)(R_U/R_S)$ to: $714.3(C/V)(R_U/R_S)$
DIDANOSINE	IMPURITIES/*Related Compounds*	*USP42–NF37*	1336	31-May-2019	1-Jun-2019	*NA*	*NA*	In *System suitability solution*: Change 0.5 mg/mL of of didanosine from

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								USP Didanosine System Suitability Mixture RS in *Diluent* to: 0.5 mg/mL of USP Didanosine System Suitability Mixture RS in *Diluent*
DRONEDARONE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP42–NF37*	1519	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Tolerances*/*30 min*: Change 20.0%–60.0% (*Q*) of the labeled amount of dronedarone free base to: 20.0%–60.0% of the labeled amount of dronedarone free base
GUANABENZ ACETATE	IM PURITIES/*Limit of 2,6-Dichlorob*	*USP42–NF37*	2129	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Column*: Change 1.8-mm ×

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	en zalde hyde/ Chromatographic system							3-mm; to: 1.8-m × 3-mm;
SUMATRIPTAN SUCCINATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	4145	31-May-2019	1-Jun-2019	*NA*	*NA*	In USP Sumatriptan Succinate Related Impurities RS: Change Mixture of sumatriptan succinate, [3-[2-(methylamino) ethyl]-1*H*-indol-5-yl]-*N*-methylmethanesulfonamide maleate salt, sumatriptan succinate related compound C, [3-[2-(dimethylamino-*N*-oxide)ethyl]-1*H*-indol-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								5-yl]-*N* -methylmethane sulfonamide, and [3-[2-(amin oethyl)]-1*H* -indo l-5-yl]-*N*-methyl methanesulfona mide. to: Mixture of sumatriptan succinate, [3-[2- (methylamino)et hyl]-1*H* -indo l-5-yl]-*N* -methylmethane sulfonamide, sumatriptan succinate related compound C, [3 -[2-(dimethylami no-*N* -o xid e)ethyl]-1*H* -indo

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								l-5-yl]-*N*-methylmethanesulfonamide, and [3-[2-(aminoethyl)]-1*H*-indol-5-yl]-*N*-methylmethanesulfonamide.
BACILLUS COAGULANS CAPSULES	ASSAY/ *Enumeration*	*USP42–NF37*	4749	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Peptone diluent*: Change Dispense into sterile containers as needed for preparing samples. Trace mineral solution. Prepare a solution containing to: Dispense into sterile containers as needed for preparing samples. *Trace mineral*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution: Prepare a solution containing
SALMETEROL INHALATION POWDER	IMPURITIES/*Organic Impurities*	*USP42–NF37*	Online	31-May-2019	1-Jun-2019	*NA*	*NA*	In Row 8 of Column 1 of *Table 3*: Change Hyrdoxynaphthoic acid to: Hydroxynaphthoic acid
CLOMIPHENE CITRATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	1068	31-May-2019	1-Jun-2019	*NA*	*NA*	In USP Clomiphene Related Compound A RS: Change (*E*,*Z*)-2-[4-(1,2-Diphenylethyl)phenoxy]-*N*,*N*-diethylethanamine hydrochloride. to: (*E*,*Z*)-2-[4-(1,2-Diphenylvinyl)phenoxy]-*N*,*N*-diethylethanam

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ine hydrochloride. Also known as (*E*,*Z*)-2-[4-(1,2-Diphenylethenyl)phenoxy]-*N*,*N*-diethylethanamine hydrochloride.
DOXORUBICIN HYDROCHLORIDE	ASSAY/*Procedure*	*USP42–NF37*	1481	31-May-2019	1-Jun-2019	*NA*	*NA*	In the *Analysis*: Change *P* = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: *P* = potency of doxorubicin hydrochloride in USP Doxorubicin Hydrochloride RS (µg/mg)
DULOXETINE DELAYED-RELEASE CAPSULES	IMPURITIES/*Organic Impurities*/*Table 2*	*USP42–NF37*	1527	31-May-2019	1-Jun-2019	*NA*	*NA*	In footnote a: Change This is a process impurity that is

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								included in *Table 1* for identification purposes only. to: This is a process impurity that is included for identification purposes only.
PIPERAZINE PHOSPHATE	*Assay*	*USP42–NF37*	3549	31-May-2019	1-Jun-2019	*NA*	*NA*	Change Each mL of 0.1 N perchloric acid is equivalent to 7.953 mg of $C_4H_{10}N_2 \cdot 2HCl$. to: Each mL of 0.1 N perchloric acid is equivalent to 9.207 mg of $C_4H_{10}N_2 \cdot H_3PO_4$.
BACILLUS COAGULANS	ASSAY/ *Enumeration*	*USP42–NF37*	4746	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Peptone diluent*: Change Dispense into sterile containers as

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								needed for preparing samples. Trace mineral solution. Prepare a solution containing to: Dispense into sterile containers as needed for preparing samples. *Trace mineral solution*: Prepare a solution containing
NEPHELOMETRY AND TURBIDIMETRY	5. FORMAZIN TURBIDITY STANDARDS	*USP42–NF37*	7059	26-Apr-2019	1-May-2019	*NA*	*NA*	In paragraph 1: Change *IUPAC Compendium of Chemical Technology,* to: *IUPAC Compendium of Chemical Terminology,*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FELODIPINE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 2*	*USP42–NF37*	1787	26-Apr-2019	1-May-2019	*NA*	*NA*	In the second variable definition list in *Analysis*: Change V_S = volume of the *Sample solution* withdrawn at each time point, *i* to: V_S = volume of the *Sample solution* withdrawn at each time point, *i* (mL)
LEVALBUTEROL INHALATION SOLUTION	IMPURITIES/*Organic Impurities*	*USP42–NF37*	2520	26-Apr-2019	1-May-2019	*NA*	*NA*	In Row 3 of *Table 3*: Change Levalbuterol — — — to: Levalbuterol 1.0 — —
THALIDOMIDE	*Assay*	*USP42–NF37*	4281	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Chromatographic system*: Change and the relative

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								standard deviation for replicate injections is not more than 1.0%. to: and the relative standard deviation for the response ratio of thalidomide to phenacetin is not more than 1.0%.
REAGENTS AND REFERENCE TABLES	REAGENT SPECIFICATIONS	*USP42–NF37*	6104	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Ferric Nitrate*: Change [10421-48-4]. to: [7782-61-8].
PSEUDOEPHEDRINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*Revision Bulletin (Official March 01, 2019)*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In the *Figure 1* caption: Change (see *Drug Release <724>, Figure 4c*) to: (see *Drug Release <724>, Figure 5c*)
CANDESARTA	PERFORMANC	*First*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In Row 2 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
N CILEXETIL AND HYDROCHLOROTHIAZIDE TABLETS	E TESTS/ *Dissolution* <*711*>	*Supplement to USP42–NF37*						Column 3 of *Table 4*: Change 0.014?/0.028?2S *(USP41)* to: 0.014 AND In Row 3 of Column 3 of *Table 4*: Change 0.014 to: 0.014/0.028 AND In *Chromatographic system*/*Column*: Change 4.6-mm × 15-cm; 5-µm packing L7. [Note—Conditioning of the *Column* with *Solution A* and *Solution B* (80:20) for NLT 20 min is recommended

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								prior to use.] to: 4.6-mm × 15-cm; 5-µm packing L7
LEVALBUTEROL HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	2518	26-Apr-2019	1-May-2019	*NA*	*NA*	In USP Levalbuterol Related Compound D RS: Change 5-{2-[(1,1-Dimethylethyl)amino]-1-hydroxyethyl}-2-hydroxy-benzaldehyde. $C_{13}H_{19}NO_3$ 237.29 ?[NOTE—This may be available as the sulfate salt (2:1).]? (USP 1-May-2019) to: 5-[2-(*tert*-Butylamino)-1-hydroxyethyl]-2-hydroxybenzaldehyde sulfate (2:1) (salt); Also known as

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								5-[2-{(1,1-Dimethylethyl)amino}-1-hydroxyethyl]-2-hydroxy-benzaldehyde sulfate (2:1). $(C_{13}H_{19}NO_3)_2 \cdot H_2SO_4$ 572.67
MORPHINE SULFATE EXTENDED-RELEASE CAPSULES	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Revision Bulletin (Official November 01, 2018)*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In USP Morphine Related Compound B RS: Change 2,2'-Bimorphine. $C_{34}H_{36}N_2O_6$ 568.66 to: 2,2'-Bimorphine trihydrate. $C_{34}H_{36}N_2O_6 \cdot 3H_2O$ 622.72
INOSITOL	IM PURITIES/*Limit of Lead*	*USP42–NF37*	5776	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Standard lead solution*: Delete A comparison solution prepared on the basis of 100 µL of the *Standard lead solution* per g of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								substance being tested contains the equivalent of 1 part of lead per million parts of substance being tested.
PHARMACEUTICAL CALCULATIONS IN PHARMACY PRACTICE	10. ALLIGATION ALTERNATE AND ALGEBRA METHODS FOR COMBINING MULTIPLE STRENGTHS OF THE SAME ACTIVE PHARMACEUTICAL INGREDIENT	*USP42–NF37*	7831	26-Apr-2019	1-May-2019	*NA*	*NA*	In *10.2 Algebra Method*/*10.2.1 Calculating by using the algebra method*/*Examples—Algebra method*: In example *2*, in equations 1, 2, 3, and 4 in all instances: Change C_s to: Q_s AND In example 2, in equation 5: Change C_w to: Q_w
ATORVASTATI	ADDITIONAL R	*USP42–NF37*	410	26-Apr-2019	1-May-2019	*NA*	*NA*	In USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
N CALCIUM	EQUIREMENTS/*USP Reference Standards <11>*							Atorvastatin Related Compound A RS: Change Desfluoro impurity, or (3*R*,5*R*)-7-[3-(phenylcarbamoyl)-2-isopropyl-4,5-diphenyl-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid, calcium salt. to: Calcium (3*R*,5*R*)-7-[2-isopropyl-4,5-diphenyl-3-(phenylcarbamoyl)-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoate (1:2); Also known as Desfluoro impurity, or (3*R*,5*R*)-7-[3-(phenylcarbamoyl)-2-isop

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ropyl-4,5-diphenyl-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid, calcium salt.
IMIPRAMINE PAMOATE CAPSULES	ASSAY/ *Procedure*	*USP42–NF37*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Solution A* and *Solution B* and *Diluent*: Change *Chromatographic acetonitrile* to: Acetonitrile
LEVALBUTEROL INHALATION SOLUTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	2520	26-Apr-2019	1-May-2019	*NA*	*NA*	In USP Levalbuterol Related Compound D RS: Change 5-[2-{(1,1-Dimethylethyl)amino}-1-hydroxyethyl]-2-hydroxy-benzaldehyde; Also known as 5-[2-{(1,1-Dimethylethyl)amino}methyl]-4-hydroxy-3-(methoxymethyl)-benzenemethanol.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$C_{13}H_{19}NO_3$ 237.29 [NOTE: This Reference Standard is available as the benzesulfonic acid salt.] to: 5-[2-(*tert* -Butylamino)-1-hydroxyethyl]-2-hydroxybenzaldehyde sulfate (2:1) (salt); Also known as 5-[2-{(1,1-Dimethylethyl)amino}-1-hydroxyethyl]-2-hydroxy-benzaldehyde sulfate (2:1). $(C_{13}H_{19}NO_3)_2 \cdot H_2SO_4$ 572.67
TRAMADOL HYDROCHLORIDE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 1/Instrumental conditions*	*USP42–NF37*	4409	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Cell*: Change 5 cm to: 5 mm

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NEPHELOMETRY AND TURBIDIMETRY	4. INSTRUMENTATION	*USP42–NF37*	7059	26-Apr-2019	1-May-2019	*NA*	*NA*	In paragraph 2: Change silicone diodes to: silicon diodes
CLONIDINE TRANSDERMAL SYSTEM	PERFORMANCE TESTS/*Drug Release <724>/Test 1*	*USP42–NF37*	1084	26-Apr-2019	1-May-2019	*NA*	*NA*	*Apparatus 7*: Change (see *Figure 4a*). to: (see *Figure 5a*).
LEVALBUTEROL INHALATION SOLUTION	IMPURITIES/*Limit of S-Albuterol*	*USP42–NF37*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Mobile phase*: Change ?*Acetonitrile*, *methanol*, and acetic acid (50:50). To each liter of the solution add 3 mL of acetic acid and 1 mL of triethylamine.? (USP 1-May-2019) to: Acetonitrile and methanol (50:50). To each liter of the solution add 3 mL of acetic acid and 1 mL

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								of triethylamine.
SODIUM BICARBONATE COMPOUNDED INJECTION	ASSAY/ *Procedure for Sodium Bicarbonate*	*USP42–NF37*	4023	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Analysis*: Change Result = [(V_S ? V_B) x N_A x F] x 100 to: Result = [(V_S ? V_B) x N_A x F x 100]/W AND Change F = equivalency factor, 84.01 mg/mL to: F = equivalency factor, 84.01 mg/mEq W = sample weight (mg)
REAGENTS AND REFERENCE TABLES	REAGENT SPECIFICATIONS	*USP42–NF37*	6079	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Beef Extract/ Microbial Content*: Change MT to: NMT
PHARMACEUTICAL CALCUL	19. MEAN KINETIC TEMP	*USP42–NF37*	7831	26-Apr-2019	1-May-2019	*NA*	*NA*	In the variable definition list:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ATIONS IN PHARMACY PRACTICE	ERATURE/*19.2 MKT Equation*							Change T_n = value for the total number of storage temperatures recorded during the observation period temperature recorded during the nth time period, e.g., *n*th week to: T_n = value for the temperature recorded during the *n*th time period, e.g., *n*th week
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE TABLETS	ASSAY/*Procedure/Chromatographic system*	*First Supplement to USP42–NF37*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Column*: Change 4.6-mm × 15-cm; 5-µm packing L7. [Note—Conditioning of the *Column* with *Solution A* and *Solution B* $^{?}(90:10)_{?}$ (ERR

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								1-Mar-2019) for about 30 min is recommended prior to use.] to: 4.6-mm × 15-cm; 5-µm packing L7
IMIPRAMINE PAMOATE CAPSULES	IM PUR ITIES/*Organic Impurities*	*USP42–NF37*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Solution A*: Change *Chromatographic acetonitrile* to: Acetonitrile AND In *Solution B*: Change *chromatographic acetonitrile* to: acetonitrile
MORPHINE SULFATE EXTENDED-RELEASE CAPSULES	IM PUR ITIES/*Organic Impurities*	*Revision Bulletin (Official November 01, 2018)*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In Row 4 of Column 1 of *Table 5*: Change Morphine related compound B[b] to: Morphine related

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								compound B (anhydrous)[b]
HYPROMELLOSE PHTHALATE	IMPURITIES/*Chloride and Sulfate <221>, Chloride*	*Harmonization (Official May 01, 2019)*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Analysis*: Change [?]Add 1 mL of silver nitrate TS to the *Standard solution* and then add a 50-mL portion of the *Sample solution*. Mix and allow to stand for 5 min protected from direct sunlight. Compare the turbidity of the solutions.?(NF 1-May-2019) to: Add 1 mL of silver nitrate TS to the *Standard solution*. Add 1 mL of silver nitrate TS to a 50-mL portion of the *Sample solution*. After mixing, allow

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								each solution to stand for 5 min protected from direct sunlight. Compare the turbidity of the solutions.
ISOPHANE INSULIN HUMAN SUSPENSION	ASSAY/ *Procedure*	*Interim Revision Announcement (Official January 01, 2019)*	Online	29-Mar-2019	1-Apr-2019	*NA*	*NA*	In *Standard solution*: Change USP Insulin Beef RS to: USP Insulin Human RS
SCOPOLAMINE HYDROBROMIDE	IDENTIFICATION/*B.*	*First Supplement to USP41–NF36*	8420	29-Mar-2019	1-Apr-2019	*NA*	*NA*	In *Sample solution*: Change 50 mg/mL of alcohol to: 50 mg/mL in water
PREDNISOLONE SODIUM PHOSPHATE	*Related compounds*	*USP41–NF36*	3416	29-Mar-2019	1-Apr-2019	*NA*	*NA*	In *Table 1*: Add Prednisolone sodium phosphate 1.00 — —
MERCAPTOPURINE	IMPURITIES/*Organic*	*USP41–NF36*	2587	29-Mar-2019	1-Apr-2019	*NA*	*NA*	Change *Sample solution*: 0.12

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Impurities							mg/mL of Mercaptopurine in *Solution A*. [NOTE—Inject the *Sample solution* within 1 h of preparation.] to: *Sample stock solution*: 0.5 mg/mL of mercaptopurine in a mixture of methanol and *Solution A* (1:9) prepared as follows. Transfer a suitable quantity of Mercaptopurine to an appropriate volumetric flask, add methanol equivalent to 10% of the final volume, and shake to dissolve. Dilute

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								with *Solution A* to volume. *Sample solution*: 0.12 mg/mL of mercaptopurine in *Solution A* from the *Sample stock solution*. [NOTE—Inject the *Sample solution* within 1 h of preparation.]
BUMETANIDE TABLETS	ASSAY/ *Procedure*	*Second Supplement to USP41–NF36*	Online	29-Mar-2019	1-Apr-2019	*NA*	*NA*	In *Sample solution*: Change Nominally 0.05 mg/mL of bumetanide prepared as follows. to: Nominally 125 µg/mL of bumetanide prepared as follows.
RUTIN	CHEMICAL INFORMATION	*USP41–NF36*	4841	29-Mar-2019	1-Apr-2019	*NA*	*NA*	Change 3-Rhamnogluco

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								side of 5,7,3',4'-tetrahydroxyflavonol; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4*H*-chromen-4-one-3-yl 6-*O*-?-L-rhamnopyranosyl-?-D-glucoside [250249-75-3]. to: 3-Rhamnoglucoside of 5,7,3',4'-tetrahydroxyflavonol trihydrate; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4*H*-chromen-4-one-3-yl 6-*O*-?-L-rhamnopyranosyl-?-D-glucoside trihydrate [250249-75-3].
METAXALONE	IDENTIFICATION/*B.*	*USP41–NF36*	2611	29-Mar-2019	1-Apr-2019	*NA*	*NA*	Change The retention

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								time of the major peak of the *Sample solution* corresponds to that of the *Sample solution*, as obtained in the *Assay*. to: The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.
MESNA TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Second Supplement to USP41–NF36*	8906	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In USP Mesna Related Compound A RS: Change 2-(Acetylthio)ethane-1-sulfonic acid. $C_4H_8O_4S_2$ 184.22

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: 2-(Acetylthio)ethane-1-sulfonic acid, potassium salt, crystal adduct with potassium chloride. $C_4H_7KO_4S_2$? KCl 296.86 AND In USP Mesna Related Compound B RS: Change 2,2?-Disulfanediylbis(ethane-1-sulfonic acid). $C_4H_{10}O_6S_4$ 282.36 to: 2,2?-Disulfanediylbis(ethane-1-sulfonic acid), dipotassium salt, crystal adduct with sodium chloride. $C_4H_8K_2O_6S_4$? NaCl 416.98

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DEXMEDETOMIDINE HYDROCHLORIDE	CHEMICAL INFORMATION	*USP41–NF36*	Online	22-Feb-2019	1-Mar-2019	*NA*	*NA*	This erratum applies to the *USP-NF* ONLINE platform only. See https://www.usp nf.com/sites/def ault/files/usp_pd f/EN/february_2 019_errata_ima ge1.pdf for correction

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 12
- Page 13
- Page 14
- Page 15
- Page 16
- Page 17
- Page 18
- Page 19
- Page 20
- …
- Next page Next ›
- Last page Last »